An Fe3O4 supported O-phenylenediamine based tetraaza Schiff base-Cu(ii) complex as a novel nanomagnetic catalytic system for synthesis of pyrano[2,3-c]pyrazoles.

In this research, we present a post-synthetic method for synthesizing a novel nanomagnetic Cu(II) Schiff base complex and investigate its efficiency in catalytic organic conversion reactions. Various spectroscopic analyses were employed to characterize the physiochemical characteristics of the resulting nanocomposite. The experimental results successfully demonstrate the catalytic application of the prepared Cu-complex in the preparation of pyrano[2,3-c]pyrazole heterocycles. This synthesis involved a one-pot three-component condensation reaction, wherein hydrazine hydrate, ethyl acetoacetate, malononitrile, and aromatic aldehydes were combined under reflux conditions using water as the solvent. Notably, the heterogenized complex exhibited exceptional catalytic performance, achieving remarkable conversion rates and selectivity, all accomplished using only 12 mg of the catalyst. Furthermore, thorough stability assessments of this catalyst were conducted through reusability and hot filtration tests, which confirmed its non-leaching properties and demonstrated excellent results over the course of five consecutive runs.

Fe3O4 supported [Cu(ii)(met)(pro-H)2] complex as a novel nanomagnetic catalytic system for room temperature C-O coupling reactions.

In this study, a newly-designed copper(ii) complex of metformin and l-proline which was immobilized on Fe3O4 MNPs was developed. The structure of the catalyst platform was fully characterized using spectroscopic analyses. Moreover, the catalytic activity of [Fe3O4@Cu(ii)(Met)(Pro-H)2] was investigated in a one-pot synthesis of a variety of functionalized ethers in reasonable to excellent yields through Ullman reaction in an aqueous environment using various aryl halides, phenol, and Cs2CO3 and without using any external Cu-reducing agents. Notably, gentle catalytic conditions, quick reaction times, applicability, low cost, and preventing dangerous chemicals and solvents during synthesis and catalytic application are some of the superior properties of the [Fe3O4@Cu(ii)(Met)(Pro-H)2] complex. Furthermore, the catalyst can be reused for several runs (at least eight times) without remarkable loss in efficiency.

The interactions between DNA methylation machinery and long non-coding RNAs in tumor progression and drug resistance.

DNA methylation is one of the main epigenetic mechanisms in cancer development and progression. Aberrant DNA methylation of CpG islands within promoter regions contributes to the dysregulation of various tumor suppressors and oncogenes; this leads to the appearance of malignant features, including rapid proliferation, metastasis, stemness, and drug resistance. The discovery of two important protein families, DNA methyltransferases (DNMTs) and Ten-eleven translocation (TET) dioxygenases, respectively, which are responsible for deregulated transcription of genes that play pivotal roles in tumorigenesis, led to further understanding of DNA methylation-related pathways. But how these enzymes can target specific genes in different malignancies; recent studies have highlighted the considerable role of Long Non-coding RNAs (LncRNAs). LncRNAs recruit these enzymes to promoter regions of genes and mediate their functions, showing great potential as therapeutic agents targeting the epigenetic regulation of various genes. Considering the importance of combining the current treatment methods, especially chemotherapies, with DNA methylation inhibitors in improving patients' outcomes, this review aimed to summarize the recent findings about the interaction between DNA methylation machinery and LncRNAs in regulating genes involved in tumorigenesis and drug resistance. So, these studies could provide insights toward developing novel strategies for cancer-targeted therapy.

THE ROLE OF OXIDATIVE STRESS IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

OBJECTIVE: The aim: To study the role of oxidative stress in patients with chronic kidney disease. PATIENTS AND METHODS: Materials and methods: By evaluating MDA and GSH in the serum, we tried to find out how oxidative stress affects CKD patients with end-stage renal dysfunction (ESRD). The study included 90 patients with ESRD disease whom were under hemodialysis treatment, and 30 healthy control people. RESULTS: Results: Urea, creatinine, and MDA levels were noticeably greater in ESRD patients compared to controls, but GSH levels were noticeably lower. In conclusion, oxidative stress can cause more problems to these patients by its involvement in the appearance of metabolic and cardiovascular diseases. CONCLUSION: Conclusions: Furthermore, GSH was reduced significantly in ESRD patients and associated negatively with the level of MDA. This indicates the strong involve¬ment of antioxidants, especially GSH, in the development of oxidative stress in ESRD patients.

Genetically engineered neural stem cells (NSCs) therapy for neurological diseases; state-of-the-art.

Neural stem cells (NSCs) are multipotent stem cells with remarkable self-renewal potential and also unique competencies to differentiate into neurons, astrocytes, and oligodendrocytes (ODCs) and improve the cellular microenvironment. In addition, NSCs secret diversity of mediators, including neurotrophic factors (e.g., BDNF, NGF, GDNF, CNTF, and NT-3), pro-angiogenic mediators (e.g., FGF-2 and VEGF), and anti-inflammatory biomolecules. Thereby, NSCs transplantation has become a reasonable and effective treatment for various neurodegenerative disorders by their capacity to induce neurogenesis and vasculogenesis and dampen neuroinflammation and oxidative stress. Nonetheless, various drawbacks such as lower migration and survival and less differential capacity to a particular cell lineage concerning the disease pathogenesis hinder their application. Thus, genetic engineering of NSCs before transplantation is recently regarded as an innovative strategy to bypass these hurdles. Indeed, genetically modified NSCs could bring about more favored therapeutic influences post-transplantation in vivo, making them an excellent option for neurological disease therapy. This review for the first time offers a comprehensive review of the therapeutic capability of genetically modified NSCs rather than naïve NSCs in neurological disease beyond brain tumors and sheds light on the recent progress and prospect in this context.